Zim Laboratories: The Press Release relating to grant of GMP Certification of Compliance by Australia's TGA to the Company for…

What happened

Zim Laboratories (ZIMLAB) filed a disclosure with the exchanges on 16 October 2026 at 12:54 PM titled "The Press Release relating to grant of GMP Certification of Compliance by Australia's TGA to the Company for its manufacturing facility".

Company snapshot

Zim Laboratories is a micro-cap company, with a market value of about ₹789 crore.

The stock last traded at ₹147.4, against a 52-week range of ₹59.31–₹159.8 (7.8% below the high).

Before this filing the shares had moved +2.6% over the month and +15.9% over three months. Average daily turnover over the last 20 sessions was about ₹2.64 crore.

Promoters held 30.36% at the end of Q1 FY27. Foreign institutions owned 0.03% and domestic institutions 1.33%.

What history shows

BCEIE has no earlier approval filing from this company on record since May 2026.

Market-wide, 1,510 approval filings with an impact score of 50 or more saw an average next-day move of +0.2%, with 47% rising.

Past reactions describe what happened before; they are not a forecast.

In the news

Recent coverage elsewhere (links open the original publisher):

• Zim Laboratories Ltd. 52 Week High Streak and Peer View — Univest, 12 Oct 2026
• Zim Laboratories vs Nifty 50: 1Y Return +113.83% vs -11.35% — Univest, 13 Oct 2026
• Zim Laboratories’ CARE credit rating reaffirmed as outlook turns negative — The Globe and Mail, 9 Oct 2026
• Zim Laboratories Share Price Near 52-Week High, 6.75% Up — Univest, 9 Oct 2026
• ZIMLA Share Price Today - Zim Laboratories Ltd. Stock Price Live NSE/BSE — Univest, 7 Oct 2026

Source

• Exchange filing (PDF)